Search results
Results from the WOW.Com Content Network
The thrombosis events associated with the COVID‑19 vaccine may occur 4–28 days after its administration and mainly affects women under 55. [6] [2] [20] Several relatively unusual types of thrombosis were specifically reported to be occurring in those with the reaction: cerebral venous sinus thrombosis and thrombosis of the splanchnic veins.
The WHO states that pregnant women can receive covid-19 vaccines and, if not already vaccinated, should have access to WHO Emergency Use Listing-approved vaccines, as the benefits of vaccination during pregnancy outweigh potential risks. [27]
Immunization during pregnancy is the administration of a vaccine to a pregnant individual. [1] This may be done either to protect the individual from disease or to induce an antibody response, such that the antibodies cross the placenta and provide passive immunity to the infant after birth.
The latest COVID vaccine is an updated booster that targets the Omicron variants that have been circulating all summer (part of the FLiRT family). The new vaccines were tweaked using the KP.2 ...
The updated COVID-19 vaccine is now available. Infectious disease doctors recommend being smart about the timing of your shot. You can expect similar side effects to the previous vaccines if you ...
A new study shows that your COVID-19 vaccine may temporarily change your menstrual cycle length and regularity. Some report heavier period flows.
In 2021 a condition resembling HIT but without heparin exposure was described to explain unusual post-vaccination embolic and thrombotic events after the Oxford–AstraZeneca COVID-19 vaccine. [20] [21] [22] It is a rare adverse event (1:1 million to 1:100,000) resulting from COVID-19 vaccines (particularly adenoviral vector vaccines). This is ...
rhesus rotavirus vaccine-tetravalent (RotaShield) 1999 US Withdrawn due to risk of intussusception. [47] Rimonabant (Acomplia) 2008 Worldwide Risk of severe depression and suicide. [14] Rofecoxib 2004 Worldwide Withdrawn by Merck & Co. Risk of myocardial infarction and stroke. [2] Rosiglitazone (Avandia) 2010 Europe Risk of heart attacks and death.